The economics of adjunctive therapies in coronary angioplasty: Drugs, devices or both?

Oh and colleagues in Can J Clin Pharmacol Vol 11(2) Fall 2004:e202-e211; September 1, 2004 have provided a cost-effectiveness analysis (CEA) demonstrating that abciximab is more cost-effective than other commonly used therapies (for example, coronary artery stenting) and that it should be more universally used in PCI patients. The incremental cost-effectiveness ratio of $2,832 to $7,173 per life year gained with abciximab demonstrates greater value than almost any drug commonly used in cardiovascular medicine. Why then have physicians not routinely embraced abciximab? © 2004 Canadian Society for Clinical Pharmacology. All rights reserved.